Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–17 of 17 results
Advanced filters: Author: Julie Overbaugh Clear advanced filters
  • In this Viewpoint, we have asked recipients of the Nature Awards for Mentoring in Science about their views on good mentoring, and how mentorship can help to achieve a positive research culture and contribute to scientific discovery in cancer research.

    • Martin Clynes
    • Anita Corbett
    • Julie Overbaugh
    Reviews
    Nature Reviews Cancer
    Volume: 19, P: 489-493
    • John Cairns
    • Julie Overbaugh
    • Stephan Miller
    Research
    Nature
    Volume: 335, P: 142-145
  • Scientists should make time for play to complement their intense work, maintain creativity and keep the ideas flowing, argues Julie Overbaugh.

    • Julie Overbaugh
    Comments & Opinion
    Nature
    Volume: 477, P: 27-28
  • Data on antibody response to SARS-CoV-2 in infants directly compared with their mothers is limited. Stoddard et al. find distinct antibody profiles in infants, including elevated levels of antibody binding to Spike, elevated ADCC, and convergent antibody binding escape profiles in the Spike fusion peptide.

    • Caitlin I. Stoddard
    • Kevin Sung
    • Julie Overbaugh
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-12
  • Antibodies capable of neutralizing a broad array of HIV-1 viral isolates from different clades have been isolated from some chronically infected individuals, but their development is thought to require several years. In this issue, Julie Overbaugh and her colleagues report that HIV-infected infants also develop broadly neutralizing antibodies—some at 1 year of age—and their occurrence early in life may shed light on HIV vaccine efforts to induce these antibodies.

    • Leslie Goo
    • Vrasha Chohan
    • Julie Overbaugh
    Research
    Nature Medicine
    Volume: 20, P: 655-658
  • Development of broadly neutralizing antibodies (bnAb) against HIV-1 in infected adults is a multi-step process unachievable by current vaccine approaches. Here the authors reconstruct the ontogeny of an infant bnAb, which develops in fewer steps, and identify its unique features that may shorten the path to HIV vaccines.

    • Cassandra A. Simonich
    • Laura Doepker
    • Julie Overbaugh
    ResearchOpen Access
    Nature Communications
    Volume: 10, P: 1-12
  • Understanding the risk of reinfection with SARS-CoV-2 in exposed cohorts provides an avenue to understanding the path to protection against SARS-CoV-2 for vaccine development.

    • Julie Overbaugh
    News & Views
    Nature Medicine
    Volume: 26, P: 1680-1681
  • HTLV-1 infection poses a risk for leukemia and other ailments. Now the elusive cellular receptor for this pathogen has finally been identified, and it is the same receptor that allows glucose to enter cells.

    • Julie Overbaugh
    News & Views
    Nature Medicine
    Volume: 10, P: 20-21
  • Some broadly neutralizing antibodies against HIV-1 recognize glycopeptide epitopes in the gp120 V1–V2 region. Now X-ray crystallography and NMR approaches, together with functional analyses of two such antibodies (PG9 and PG16), reveal how glycan binding specificity is achieved. The authors also created a chimeric Fab that showed improved neutralization activity.

    • Marie Pancera
    • Syed Shahzad-ul-Hussan
    • Peter D Kwong
    Research
    Nature Structural & Molecular Biology
    Volume: 20, P: 804-813
  • Millions of people are infected with human immunodeficiency virus (HIV) globally. Antiretroviral therapy offers substantial benefit to those infected or at risk of infection — controlling viraemia and delaying the onset of acquired immune deficiency syndrome (AIDS). Here, the authors describe the basic and clinical research advances in this important global health issue.

    • Steven G. Deeks
    • Julie Overbaugh
    • Susan Buchbinder
    Reviews
    Nature Reviews Disease Primers
    Volume: 1, P: 1-22
  • RNA viruses have extremely high mutation rates, which are crucial for the ability of these viruses to adapt but can also lead to population extinction. Here, Andino and colleagues describe the mechanisms that RNA viruses use to cope with the high mutational load and discuss the impact of mutational robustness on population dynamics, pathogenicity and antiviral therapies.

    • Adam S. Lauring
    • Judith Frydman
    • Raul Andino
    Reviews
    Nature Reviews Microbiology
    Volume: 11, P: 327-336